View
148
Download
1
Category
Preview:
Citation preview
IPPOSI National Strategic Forum for Clinical Research
Clinical Research in Singapore
Edward W. Holmes, MD Chairman NMRC
Deputy Chairman BMRC
Young country: Achieved independence in 1965
English speaking workforce: Population-98% literate in English Only Asian country with English as first language
Open immigration policy: 5 mil population, of which 1 mil are non-Singaporeans
Visionary leadership: Efficient, effective, ethical
Knowledge-based economy
Pro-Business Environment Lowest risk business hub #1 Labour Force Strong IP protection laws
India: 1 bil pop GDP(2004): US$ 665bn GDP growth rate: 7%
SE Asia: 520 mil pop GDP(2004): US$ 900bn GDP growth rate: 5%
Australasia: 24 mil pop GDP(2004): US$ 700bn GDP growth rate: 3.5%
China: 1.3 bil pop GDP(2004): US$ 1,600bn
GDP growth rate: 8%
India: 1 bil pop GDP(2005): US$772 bn GDP growth rate: 7.8%
SE Asia: 510 mil pop GDP(2005): US$850 bn GDP growth rate: 5.0%
Australasia: 24 mil pop GDP(2005): US$890 bn GDP growth rate: 2.4%
China: 1.3 bil pop GDP(2005): US$1,930 bn GDP growth rate: 9.3%
*2005 figures are estimates
Half the world’s population in 7 hours
Singapore At a Glance The ‘Heart’ of Asia
Biomedical Sciences Initiative
In 2000 government launched a new initiative to make biomedical sciences one of the pillars of the economy
Phase I focus on buildup of basic biomedical expertise
Biopolis
Phase 2 2 buildings for corporate labs Additional 400,000 sqft Construction commenced in June ‘05 Officially opened on 30 October ‘06
Phase 1 2 million sqft S$500 million invested Public R&D centres & corporate labs
Shared Facilities Shared R&D equipment Shared utilities Shared animal facility
Phase 4
Phase 3
Phase 3 Request for proposal from developers
by 3Q07 Expected to be ready by 2Q09
2,000 scientists 20 private companies
2.4 mil sqft
Building R&D Capabilities
Before 2000
Institute of Molecular & Cell Biology
(IMCB) ED: Neil Copeland 400 RSEs
*Set-up as BTU in 1990. Became BTC in 1995, established as BTI in 2003 ^ The Centre for Molecular Medicine (CMM) was established in 2004, and was repositioned to Institute of Medical Biology in 2007
Institute of Medical Biology ̂
ED:Birgitte Lane
2005
Singapore Bioimaging Consortium
Chairman: Sir George Radda
Singapore Stem Cell
Consortium Chairman:
Roger Pedersen
Singapore Institute for Clinical Sciences
ED: Judith Swain
Singapore Immunology
Network Chairman: Philippe Kourilsky
2006
Genome Institute of Singapore
(GIS) ED:
Edison Liu 220 RSEs
2003 2001 2000
Bioprocessing Technology
Institute (BTI)* ED:
Miranda Yap 75 RSEs
Institute of Bioengineering &
Nanotechnology (IBN) ED: Jackie Ying
120 RSEs
Bioinformatics Institute (BII) ED: Frank Eisenhaber 120 RSEs
2002
Institute of Chemical
Engineering Sciences (ICES)
ED: Keith Carpenter 170 RSEs
Translational R&D
Background to BMS Phase II In Jun 06, Singapore Government decided that translational & clinical research (TCR) will be a key focus of BMS Phase 2 development
TCR included as part of MOH’s mandate
Multi-agency BMS Exco reconstituted in Jul 06, co-chaired by Chairman, A*STAR & PS(Health)
Formulates policies for all national TCR programs
Integrated Biomedical Sciences Initiative
Research, Innovation & Enterprise Council (RIEC) Chaired by PM Lee Hsien Loong
Steering Committee for Life Sciences (SCLS) Dy Chmn RIEC / Chmn NRF, Ministers of Trade & Industry, Health and Education
Biomedical Sciences Executive Committee Co-chaired by Chairman, A*STAR & Permanent Secretary (Health)
Infrastructure Capital WG
Intellectual Capital WG
Human Capital WG
Biomedical Research Council (BMRC), A*STAR
(Chmn: Prof Sir George Radda) (Deputy Chmn: Prof E. Holmes)
National Medical Research Council (NMRC),
Ministry of Health (Exec Chmn: Prof Edward Holmes)
BMS International Advisory Council
(BMS IAC)
National R&D Framework 2006 - 2010
Public / Private Universities Corporate Research Units
Hospitals Polytechnics A*STAR RIs
Others e.g. Think-tanks, Institutes
Private Labs
S$5b S$1.05b S$7.5b
S$5.4b S$2.1b
A*STAR
CABINET
MTI MOE
EDB Academic Research
Fund (AcRF)
Research, Innovation & Enterprise Council (RIEC)
National Research Foundation (NRF)
New Initiatives and programs to develop new growth areas &
new capabilities
R&D Performers
S$13.55b
S$1.55b for Translational
& Clinical Research
MOH
Key Recommendations
INDUSTRY
BENCH Key performers: A*STAR BMRC RIs,
universities
BEDSIDE Key performers:
MOH (viz. hospitals, specialist centres)
>> Grow health services, public health research
>> Build critical mass of human capital, supernumerary to clinical service needs
>> Establish flagship programmes from bench-to-bedside (heart/ metabolic, neuro, cancer, eye, infectious disease)
Driven by A*, EDB,
Bio*One Driven by
EDB, Bio*One
>> Develop best enabling resources in Asia for translational research
>> Strengthen regulatory framework for translational and clinical research.
Driven by multi-agency BMS
Exco
Interaction strengthened by new entities arising from hospital-medical school partnerships
>> Develop strong investigational med capability
>> Be preferred site for early phase
clinical trials in Asia
• Singapore Translational Research Investigator Awards (STaR): full salary & $1M pa grant
• Clinician Scientist Awards (CSA): full salary & $250K pa grant
Master of Clinical Investigation 8 awardees (Target 15/year) AST-PhD Scholarship 5 awardees (Target 4/year) MD- PhD trainees 2 awardees (Target 10/year) MBBS-PhD (local and UK) 24 (Target 6/year) ________________
Clinician Investigator • In depth training in clinical
specialty • Limited research training • Spends >70% time engaged
in patient care; collaborator with clinician or basic scientist
• Non-hospital support for time spent in research collaboration
• Aims to establish Singapore as a leader in 5 strategic disease-orientated areas
• It achieves this by building on existing, local, highly competitive programmes and providing highly productive platforms for collaboration with top overseas research institutions and industry
• The 5 TCR programmes awarded are:
• Each award is worth S$25mil over 5 years
Singapore Tissue Network (STN) National resource for collection, storage, and retrieval of human tissue samples to support translational and clinical research
Singapore Consortium for Cohort Studies (SCCS)
Common infrastructure for coordination of cohort studies and collection of
phenotypic data
Clinical Research Infrastructure in Singapore Clinical Imaging Research Centre (CIRC)
• National resource for research imaging in humans open to all biomedical researchers in Singapore
• Aims: – Participating in research studies – Development & testing of new imaging
technologies – Focus on key areas of national biomedical
research interest – Training of faculty & students
Pre-Clinical Research Infrastructure in Singapore
National Breeding Centre for SPF research animals • Local supply of mice & rats and support services
• Breed high quality standard strains required by Singapore investigators
Development of National Large Animal Research Facility
• Minipigs
• Non-human primates
Formation of 1st AMC: NUHS in 2008
Developing 2nd AMC: SGH and Duke-NUS GMS
Stand alone corporate entity; independent board
NUS School of Medicine (MOE) and National University Hospital (MOH) fused
Cancer and Heart Centers established
Chief Executive over SoM and NUH
Singapore General Hospital; SERI, NCC, NHC
Duke/NUS Graduate Medical School-opened 2006
Separate corporate entities at present
Strategic Infrastructure Grants
New research buildings
Investigational Medicine Units (IMU)
Animal research labs
Investigational Medicine
Phase 1 Phase 3 Phase 2 Phase 4,
Epidemiology, HSOR studies
Investigational Medicine Unit At Kent Ridge Campus
Investigational Medicine Unit At Outram Campus
Singapore Clinical Research Institute (SCRI)
• National, one-stop centre for private/public investigators who wish to conduct late-phase clinical research in Singapore
• Provides services such as study design, project & data management, biostatistics, study reporting on a fee-for-service basis
• Develops specialized training courses • Conducts in-house research
Clinical Research Infrastructure in Singapore Investigational Medicine Units
Singapore’s Focus in Clinical Research
Asian Phenotype
Focus on Diseases of Interest to Singapore or Special Ability to Study in Singapore
Investigational Medicine and POC Studies
Recommended